Files and links (1)
CC BY V4.0, Open Access
Journal article
Inflammation in HIV and Its Impact on Atherosclerotic Cardiovascular Disease
Circulation research, Vol.134(11), pp.1515-1545
2024
PMID: 38781301
Abstract
People living with HIV have a 1.5- to 2-fold increased risk of developing cardiovascular disease. Despite treatment with highly effective antiretroviral therapy, people living with HIV have chronic inflammation that makes them susceptible to multiple comorbidities. Several factors, including the HIV reservoir, coinfections, clonal hematopoiesis of indeterminate potential (CHIP), microbial translocation, and antiretroviral therapy, may contribute to the chronic state of inflammation. Within the innate immune system, macrophages harbor latent HIV and are among the prominent immune cells present in atheroma during the progression of atherosclerosis. They secrete inflammatory cytokines such as IL (interleukin)-6 and tumor necrosis-α that stimulate the expression of adhesion molecules on the endothelium. This leads to the recruitment of other immune cells, including cluster of differentiation (CD)8
and CD4
T cells, also present in early and late atheroma. As such, cells of the innate and adaptive immune systems contribute to both systemic inflammation and vascular inflammation. On a molecular level, HIV-1 primes the NLRP3 (NLR family pyrin domain containing 3) inflammasome, leading to an increased expression of IL-1β, which is important for cardiovascular outcomes. Moreover, activation of TLRs (toll-like receptors) by HIV, gut microbes, and substance abuse further activates the NLRP3 inflammasome pathway. Finally, HIV proteins such as Nef (negative regulatory factor) can inhibit cholesterol efflux in monocytes and macrophages through direct action on the cholesterol transporter ABCA1 (ATP-binding cassette transporter A1), which promotes the formation of foam cells and the progression of atherosclerotic plaque. Here, we summarize the stages of atherosclerosis in the context of HIV, highlighting the effects of HIV, coinfections, and antiretroviral therapy on cells of the innate and adaptive immune system and describe current and future interventions to reduce residual inflammation and improve cardiovascular outcomes among people living with HIV.
Details
- Title
- Inflammation in HIV and Its Impact on Atherosclerotic Cardiovascular Disease
- Authors/Creators
- Laventa M Obare - Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN (L.M.O., S.A.M., C.N.W.)Tecla Temu - Department of Pathology, Harvard Medical School, Boston, MA (T.T.)Simon A Mallal - Institute for Immunology and Infectious Diseases, Murdoch University, WA, Western Australia (S.A.M.)Celestine N Wanjalla - Vanderbilt University Medical Center
- Publication Details
- Circulation research, Vol.134(11), pp.1515-1545
- Publisher
- published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc.
- Identifiers
- 991005670269807891
- Copyright
- © 2024 The Authors.
- Murdoch Affiliation
- Institute for Immunology and Infectious Diseases
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Metrics
32 File views/ downloads
75 Record Views